Floatz logo

Teikoplanin

Sclerosing Cholangitis

Tongji HospitalmixturePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Sclerosing Cholangitis cohort.

Asset / SponsorPhaseRating
Sulperazon
Tongji Hospital
Phase 4BB
Meropenem
Tongji Hospital
Phase 4B

Same molecule, other indications

Teikoplanin is also rated in:

cystic fibrosisDormant
CC
Indicative · Phase 1
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →